MediWound Ltd. Stock price

Equities

MDWD

IL0011316309

Pharmaceuticals

Real-time Estimate Cboe BZX 10:11:06 2024-03-28 am EDT 5-day change 1st Jan Change
15.15 USD +0.33% Intraday chart for MediWound Ltd. -4.08% +50.44%
Sales 2024 * 24.04M Sales 2025 * 31.94M Capitalization 140M
Net income 2024 * -17M Net income 2025 * -17M EV / Sales 2024 * 5.81 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 4.38 x
P/E ratio 2024 *
-7.91 x
P/E ratio 2025 *
-8.73 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.3%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M MT
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sector Update: Health Care Stocks Mixed Late Afternoon MT
MediWound Shares Rise After Positive Results From EscharEx Comparison Study MT
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study CI
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA MT
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns CI
MediWound Secures $6.7 Million in DoD Funding for Field Burn Treatment Therapy MT
Mediwound Ltd. Secures Additional U.S. Department of Defense Funding to Advance Nexobrid® Development for the U.S. Army CI
Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads CI
Transcript : MediWound Ltd., Q3 2023 Earnings Call, Nov 21, 2023
Earnings Flash (MDWD) MEDIWOUND Reports Q3 Revenue $4.8M, vs. Street Est of $4.8M MT
MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023 CI
More news
1 day-2.96%
1 week-3.33%
Current month+4.43%
1 month+2.86%
3 months+46.74%
6 months+64.13%
Current year+48.48%
More quotes
1 week
15.02
Extreme 15.02
16.89
1 month
13.29
Extreme 13.29
17.25
Current year
10.20
Extreme 10.2
17.25
1 year
7.10
Extreme 7.1
17.25
3 years
7.10
Extreme 7.1
43.54
5 years
7.10
Extreme 7.1
43.54
10 years
7.10
Extreme 7.1
108.50
More quotes
Managers TitleAgeSince
Founder 78 99-12-31
Chief Executive Officer 49 03-08-31
Director of Finance/CFO 52 23-05-13
Members of the board TitleAgeSince
Director/Board Member 67 17-03-31
Director/Board Member 66 20-04-26
Chairman 70 22-07-31
More insiders
Date Price Change Volume
24-03-28 15.3 +1.32% 7 510
24-03-27 15.1 -2.96% 58,765
24-03-26 15.56 -1.71% 220,636
24-03-25 15.83 -0.88% 89,284
24-03-22 15.97 +0.13% 242,771

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.1 USD
Average target price
28.5 USD
Spread / Average Target
+88.74%
Consensus
  1. Stock
  2. Equities
  3. Stock MediWound Ltd. - Nasdaq